12 results
Primary objective first part: analyse a set of 1951 genes for prediction of response measured by progression free survival ratio (TTP1:TTP2) on mTOR inhibition.Primary objective second part: to assess the ratio of progression free survival (TTP1:…
To describe and compare pharmacokinetics of everolimus in a 10 mg QD and everolimus 5mg BID schedule, evaluated PK parameters will be a.o. Cmax/Cmin ratio, AUC, Cmax, Cmin, Tmax.
To determine the efficacy of the combination of everolimus and capecitabine in a group of patients with metastatic or locally advanced HCC with Child-Pugh class B liver cirrhosis. In addition, to investigate biomarkers of HCC before and during the…
With the goal of improving kidney function and without causing an increased number of rejections, is it possible to reduce tacrolimus dosage through the use of the previously-mentioned immunosupressives after month three.
The aim of this study is to investigate if conversion of tacrolimus-based immunosuppression to everolimus-based immunosuppression results in preservation of renal function as compared to continued tacrolimus-based immunosuppression. Apart from renal…
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
A randomised controlled trial is performed to evaluate the clinical effectiveness of the skin stretching technique for two categories:a. acute burn wounds: wound closure by means of skin stretching should lead to a significant reduction of scar…
Primary objective* To evaluate the efficacy in terms of overall survival (OS) of erlotinib, everolimus and dasatinib in combination with radiation therapy, in patients with a DIPG both: - compared to the other experimental treatments by comparisons…
This study aims to investigate the progression-free survival (PFS) according to RECIST 1.1 criteria on matched targeted therapy by STA-analysis (PFS2) in comparison to the PFS recorded on the therapy administered immediately prior to enrolment (PFS1…
The primary objective is to demonstrate the efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide to prolong progression freesurvival in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine…
-To assess the safety and tolerability of CLDN6 CAR-T +/- CLDN6 RNALPX and to assess the comparability of CLDN6 CAR-T from the manualand automated processes-To identify the maximum tolerated dose (MTD)/RP2D for each IMP (i.e. CLDN6 CAR-T +/- CLDN6…
The purpose of this study is to investigate the efficacy and safety of the investigational drug known as Lutetium (177Lu) edotreotide in comparison with several other drugs that are already used worldwide in the treatment of neuroendocrine tumors.It…